Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples